A small trial by investigators at the National Cancer Institute holds promise to bring personalized cell therapy into the solid tumor arena, after more than a decade of success in blood cancers. A new ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...